In a multicenter retrospective analysis, CRP and alpha-fetoprotein were found to score immunotherapy in patients with hepatocellular carcinoma treated with atezolizumab in combination with bevacizumab, and patients with AFP ≥ 100 ng/mL and CRP ≥1 mg/dL were found to have a poorer prognosis (21). The gene discussed is AFP; the disease is hepatocellular carcinoma.